Clinical Trials Advisory Committee
The primary purpose of the Clinical Trials Advisory Committee (CTAC) is to advise the Oversight Committee on important issues of the clinical trials. The CTAC shall give their expert opinion on the impact of current CPRIT mechanisms supporting clinical trials; give advice on opportunities to increase CPRIT’s impact on translating basic discoveries to clinical trials; and advise on mechanisms that would address barriers to patient enrollment in therapeutic clinical trials.
Related Documents:
Clinical Trials Advisory Committee Annual Report 2024Clinical Trials Advisory Committee Annual Report 2023
Members:
David E. Gerber, M.D., Chair
|
Carlos L. Arteaga, M.D.
|
Ruma Bhagat M.D., MPH
|
Suzanne Cole, M.D., FACP, FASCO
|
S. Gail Eckhardt, M.D., FASCO
|
David S. Hong M.D.
|
Ronan J. Kelly M.D., MBA
|
Martha P. Mims, M.D., Ph.D.
|
Pavan Reddy, M.D.
|
C Patrick Reynolds, M.D., Ph.D.
|